㈱PRISM BioLab
Tokyo, JP · 3 known investors
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
AI & Machine LearningBiotechDeep Tech
Investors · 3
Frequently asked questions
- What does ㈱PRISM BioLab do?
- PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
- Who are ㈱PRISM BioLab's investors?
- ㈱PRISM BioLab's investors include DBJ Capital, Eisai Innovation, Inc., Newton Biocapital.
- Where is ㈱PRISM BioLab headquartered?
- ㈱PRISM BioLab is headquartered in Tokyo, JP.